14 Notably, the majority of the epidemiological investigations included in this study (with the exception of two regional studies in Germany and one early study from Denmark) consistently indicated a continuous upward trend in AP incidence across Europe, with a median annual increase of 2.3%
With cardiovascular health also being of concern for overweight individuals, this is also especially concerning
(2010) Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
These medications have the possibility of causing episodes of low blood sugar, which may include dizziness, lightheadedness, confusion, drowsiness, weakness and shakiness